RBC keeps Sciele at sector perform

Sciele Pharma, Inc. was kept at a sector perform, above average risk rating by RBC Capital Markets analyst Ken Trbovich. RBC raised its third-quarter 2006 revenue estimate to $75.0 million, from $70.5 million. Changes in the analyst's model are the result of adjusting price/prescription assumptions for recent price increases. Sular and Triglide are tracking slightly ahead and Altoprev is behind RBC's expectations, while Fortamet prescriptions are basically flat. Altoprev was down 28% and 29% in July and August respectively. Shares of the Atlanta-based pharmaceutical company were up 6 cents, or 0.31%, at $19.16. (Nasdaq: SCRX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.